Dawnrays Pharmaceutical (Holdings) logo

2348 - Dawnrays Pharmaceutical (Holdings) Share Price

HK$1.05 0.0  1.0%

Last Trade - 25/11/20

Small Cap
Market Cap £155.7m
Enterprise Value £103.0m
Revenue £107.7m
Position in Universe 2256th / 5951
Unlock 2348 Revenue
Relative Strength (%)
1m +4.07%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -33.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
783.8 985 824.4 882.5 948.9 950 +3.9%
+25.8 +46.3 -11.5 +10.5 +3.8 -10.4
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, DawnraysPharmaceutical Holdings Ltd revenues decreased less than 1%to RMB489M. Net income decreased 14% to RMB129.7M. Revenuesreflect Finished Drugs segment increase of 3% to RMB381.7M,also reflect Intermediates and Bulk Medicines segmentdecrease of 10% to RMB107.3M. Net income was partiallyoffset by Finished Drugs segment income decrease of 10% toRMB214.2M. Dividend per share remained flat at RMB0.01.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 2348
Graphical History


2348 Revenue Unlock 2348 Revenue

Net Income

2348 Net Income Unlock 2348 Revenue

Normalised EPS

2348 Normalised EPS Unlock 2348 Revenue

PE Ratio Range

2348 PE Ratio Range Unlock 2348 Revenue

Dividend Yield Range

2348 Dividend Yield Range Unlock 2348 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
2348 EPS Forecasts Unlock 2348 Revenue
Profile Summary

Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated September 20, 2002
Public Since July 11, 2003
No. of Shareholders: n/a
No. of Employees: 1,045
Sector Healthcare
Industry Pharmaceuticals
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 1,534,781,000
Free Float (0.0%)
Eligible for
2348 Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for 2348
Upcoming Events for 2348
Frequently Asked Questions for Dawnrays Pharmaceutical (Holdings)
What is the Dawnrays Pharmaceutical (Holdings) share price?

As of 25/11/20, shares in Dawnrays Pharmaceutical (Holdings) are trading at HK$1.05, giving the company a market capitalisation of £155.7m. This share price information is delayed by 15 minutes.

How has the Dawnrays Pharmaceutical (Holdings) share price performed this year?

Shares in Dawnrays Pharmaceutical (Holdings) are currently trading at HK$1.05 and the price has moved by -23.91% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Dawnrays Pharmaceutical (Holdings) price has moved by -31.93% over the past year.

What are the analyst and broker recommendations for Dawnrays Pharmaceutical (Holdings)?

Of the analysts with advisory recommendations for Dawnrays Pharmaceutical (Holdings), there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Dawnrays Pharmaceutical (Holdings) is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Dawnrays Pharmaceutical (Holdings) next release its financial results?

Dawnrays Pharmaceutical (Holdings) is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Dawnrays Pharmaceutical (Holdings) dividend yield?

The Dawnrays Pharmaceutical (Holdings) dividend yield is 5.84% based on the trailing twelve month period.

Does Dawnrays Pharmaceutical (Holdings) pay a dividend?

Last year, Dawnrays Pharmaceutical (Holdings) paid a total dividend of 0.05, and it currently has a trailing dividend yield of 5.84%. Looking ahead, Dawnrays Pharmaceutical (Holdings) has not announced an ex-dividend date yet.

When does Dawnrays Pharmaceutical (Holdings) next pay dividends?

Dawnrays Pharmaceutical (Holdings) has yet to annouce their ex-dividend date. The historic dividend yield on Dawnrays Pharmaceutical (Holdings) shares is currently 5.84%.

How do I buy Dawnrays Pharmaceutical (Holdings) shares?

To buy shares in Dawnrays Pharmaceutical (Holdings) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Dawnrays Pharmaceutical (Holdings)?

Shares in Dawnrays Pharmaceutical (Holdings) are currently trading at HK$1.05, giving the company a market capitalisation of £155.7m.

Where are Dawnrays Pharmaceutical (Holdings) shares listed? Where are Dawnrays Pharmaceutical (Holdings) shares listed?

Here are the trading details for Dawnrays Pharmaceutical (Holdings):

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 2348
What kind of share is Dawnrays Pharmaceutical (Holdings)?

Based on an overall assessment of its quality, value and momentum, Dawnrays Pharmaceutical (Holdings) is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Dawnrays Pharmaceutical (Holdings) share price forecast 2020?

Shares in Dawnrays Pharmaceutical (Holdings) are currently priced at HK$1.05. At that level they are trading at 0.516% discount to the analyst consensus target price of 0.00.

How can I tell whether the Dawnrays Pharmaceutical (Holdings) share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dawnrays Pharmaceutical (Holdings). Over the past six months, the relative strength of its shares against the market has been -14.63%. At the current price of HK$1.05, shares in Dawnrays Pharmaceutical (Holdings) are trading at 0.42% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Dawnrays Pharmaceutical (Holdings) PE Ratio?

The Dawnrays Pharmaceutical (Holdings) PE ratio based on its reported earnings over the past 12 months is 5.69. The shares are currently trading at HK$1.05.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Dawnrays Pharmaceutical (Holdings)?

Dawnrays Pharmaceutical (Holdings)'s management team is headed by:

Yung Lai Hung - EDR
Tung Ming Li - EDR
Kit Ling Pang - SEC
Hong Man Leung - NED
Tung Sing Lo - NID
Hao Xi Ede - NID
Shaojun Chen - CEO
Bo Hui - DRC
Ming Yee Lam - NID
Who are the major shareholders of Dawnrays Pharmaceutical (Holdings)?

Here are the top five shareholders of Dawnrays Pharmaceutical (Holdings) based on the size of their shareholding:

Fortune United Group Limited Corporation
Percentage owned: 38.32% (588.1m shares)
Li (Kei Ling) Individual Investor
Percentage owned: 6.95% (106.6m shares)
Toyo International Investment Ltd. Corporation
Percentage owned: 6.52% (100.0m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 5.76% (88.4m shares)
Li (Tung Ming) Individual Investor
Percentage owned: 5.23% (80.2m shares)
Similar to 2348
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.